These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 30801672

  • 1. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
    Wiegmann H, Valentin F, Tarinski T, Liebau E, Loser K, Traupe H, Oji V.
    Br J Dermatol; 2019 Nov; 181(5):999-1008. PubMed ID: 30801672
    [Abstract] [Full Text] [Related]

  • 2. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
    Sugimoto S, Morizane S, Nomura H, Kobashi M, Sugihara S, Iwatsuki K.
    J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
    Kasparek P, Ileninova Z, Zbodakova O, Kanchev I, Benada O, Chalupsky K, Brattsand M, Beck IM, Sedlacek R.
    PLoS Genet; 2017 Jan; 13(1):e1006566. PubMed ID: 28095415
    [Abstract] [Full Text] [Related]

  • 8. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
    Gouin O, Barbieux C, Leturcq F, Bonnet des Claustres M, Petrova E, Hovnanian A.
    J Invest Dermatol; 2020 Jun; 140(6):1184-1194. PubMed ID: 32169475
    [Abstract] [Full Text] [Related]

  • 9. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
    Zingkou E, Pampalakis G, Sotiropoulou G.
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct 01; 1866(10):165831. PubMed ID: 32442469
    [Abstract] [Full Text] [Related]

  • 10. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
    Furio L, Pampalakis G, Michael IP, Nagy A, Sotiropoulou G, Hovnanian A.
    PLoS Genet; 2015 Sep 01; 11(9):e1005389. PubMed ID: 26390218
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Keratinocyte-specific mesotrypsin contributes to the desquamation process via kallikrein activation and LEKTI degradation.
    Miyai M, Matsumoto Y, Yamanishi H, Yamamoto-Tanaka M, Tsuboi R, Hibino T.
    J Invest Dermatol; 2014 Jun 01; 134(6):1665-1674. PubMed ID: 24390132
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases.
    Raghunath M, Tontsidou L, Oji V, Aufenvenne K, Schürmeyer-Horst F, Jayakumar A, Ständer H, Smolle J, Clayman GL, Traupe H.
    J Invest Dermatol; 2004 Sep 01; 123(3):474-83. PubMed ID: 15304086
    [Abstract] [Full Text] [Related]

  • 18. Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.
    Walker AL, Denis A, Bingham RP, Bouillot A, Edgar EV, Ferrie A, Holmes DS, Laroze A, Liddle J, Fouchet MH, Moquette A, Nassau P, Pearce AC, Polyakova O, Smith KJ, Thomas P, Thorpe JH, Trottet L, Wang Y, Hovnanian A.
    Bioorg Med Chem Lett; 2019 Oct 15; 29(20):126675. PubMed ID: 31521475
    [Abstract] [Full Text] [Related]

  • 19. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S, Olt S, Schoefmann N, Stuetz A, Winiski A, Wolff-Winiski B.
    Exp Dermatol; 2014 Jul 15; 23(7):524-6. PubMed ID: 24848304
    [Abstract] [Full Text] [Related]

  • 20. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
    Meyer-Hoffert U, Wu Z, Schröder JM.
    PLoS One; 2009 Jul 15; 4(2):e4372. PubMed ID: 19190773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.